ESGCT e-Seminars

The ESGCT e-Seminars will be live on YouTube and previous videos available to view on our website.


  


Series 3: Viral vs. non-viral genetic engineering of T cells

In collaboration with the American Society of Gene & Cell Therapy

 



 


Tuesday 1 February 2022, 16:00-17:00 CET

Considerations for engineering allogeneic cell therapies


Marco Alessandrini, Antion Bioscience


Watch Recording




 


Tuesday 8 February 2022, 16:00-17:00 CET

Virus-free gene editing of T cells
 

Dimitrios Wagner, Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, Germany

Watch Recording



 

Tuesday 15 February 2022, 16:00-17:00 CET

Combining Oncolytic Viruses and CAR-T Therapies


Saul Priceman, City of Hope, CA

 

Watch Live on YouTube

 

Tell us what you think! Complete our short survey and let us know what you would like to see in future e-Seminars. Your feedback helps us develop resources to better support the gene and cell therapy community. Thank you! 

COMPLETE SURVEY


Previous Talks

Series 1: The SARS-CoV2 Pandemic

Wherever possible, the talks which have already taken place are available to view by following the links below.

27 May 2020  |  View Video
Current insights on the origin of SARS-CoV2
Dong-Yan JIN, The University of Hong Kong


03 June 2020  |  View Video
The COVID-19 Pandemic: Images from a "SPELL" on America
Daniel Lucey, O’Neill Institute for National and Global Health
                    Law, Washington DC
10 June 2020  |  View Video
Novel vaccine strategies targeting SARS-CoV2
Ami Patel, The Wistar Institute, Philadelphia, PA
17 June 2020  | 
SARS-CoV2 – spotlight on cell entry
Stefan Pöhlmann, Deutsches Primatenzentrum, Göttingen

e-Seminars: SARS-CoV2 Pandemic

Series 2: Gene Editing

With the kind support of



Wherever possible, the talks which have already taken place are available to view by following the links below.
 

3 February 2021  |  Video available for ESGCT members only
Repurposing of bacterial CRISPR-Cas immunity for genome editing
Virgis Siksnys, Vilnius University, Institute of Biotechnology


10 February 2021  |  View Video
Safety considerations in therapeutic genome editing
Toni Cathomen, University of Freiburg


17 February 2021  |  View Video
Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease
Laura Sepp-Lorenzino, Ph.D., Executive Vice President, Chief Scientific Officer, Intellia Therapeutics


e-Seminars: Gene Editing